Mutation patterns in small cell and non-small cell lung cancer patients suggest a different level of heterogeneity between primary and metastatic tumorsSaber, A., Hiltermann, T. J. N., Kok, K., Terpstra, M. M., de Lange, K., Timens, W., Groen, H. J. M. & van den Berg, A., 4-Jan-2017, In : CARCINOGENESIS. 38, 2, p. 144-151 8 p.
Research output: Contribution to journal › Article › Academic › peer-review
- Groningen Research Institute for Asthma and COPD (GRIAC)
- Damage and Repair in Cancer Development and Cancer Treatment (DARE)
- Guided Treatment in Optimal Selected Cancer Patients (GUTS)
- Stem Cell Aging Leukemia and Lymphoma (SALL)
- Translational Immunology Groningen (TRIGR)
- Center for Medical Imaging (CMI)
Several studies have shown heterogeneity in lung cancer, with parallel existence of multiple subclones characterized by their own specific mutational landscape. The extent to which minor clones become dominant in distinct metastasis is not clear. The aim of our study was to gain insight in the evolution pattern of lung cancer by investigating genomic heterogeneity between primary tumor and its distant metastases. Whole exome sequencing (WES) was performed on 24 tumor and five normal samples of two small cell lung carcinoma (SCLC) and three non-SCLC (NSCLC) patients. Validation of somatic variants in these 24 and screening of 33 additional samples was done by single primer enrichment technology. For each of the three NSCLC patients, about half of the mutations were shared between all tumor samples, whereas for SCLC patients, this percentage was around 95. Independent validation of the non-ubiquitous mutations confirmed the WES data for the vast majority of the variants. Phylogenetic trees indicated more distance between the tumor samples of the NSCLC patients as compared to the SCLC patients. Analysis of 30 independent DNA samples of 16 biopsies used for WES revealed a low degree of intra-tumor heterogeneity of the selected sets of mutations. In the primary tumors of all five patients, variable percentages (19-67%) of the seemingly metastases-specific mutations were present albeit at low read frequencies. Patients with advanced NSCLC have a high percentage of non-ubiquitous mutations indicative of branched evolution. In contrast, the low degree of heterogeneity in SCLC suggests a parallel and linear model of evolution.
|Number of pages||8|
|Publication status||Published - 4-Jan-2017|
- INTRATUMOR HETEROGENEITY, CLINICAL-IMPLICATIONS, GENOMIC INSTABILITY, ACQUIRED-RESISTANCE, PANCREATIC-CANCER, SEQUENCING DATA, BREAST CANCERS, T790M MUTATION, EVOLUTION, ADENOCARCINOMA